Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 42.41 as of 2026-10-06T15:12:31.003Z.
Consensus retrieved: 2026-10-06T12:28:30.524Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:12:31.003Z.
Quote observation: 2026-10-06T15:10:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d6f8dd0191412ef2243aa1201f16a7b462a81073467013b08e096891a203e936
Forward PE Ratio (42.41) = Dated Quote Price ($31.30) / Consensus Forward EPS ($0.74)
FORWARD PE RATIO
42.41
SECTOR MEDIAN · HEALTHCARE
19.04
median of 163 covered companies
CURRENT VS SECTOR MEDIAN
+122.74%
vs the sector median at left
HealthStream, Inc.
Market Cap
$914.43M
Forward PE Ratio
42.41
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| HealthStream, Inc. (HSTM) | $914.43M | 42.41 |
| Arbutus Biopharma Corp (ABUS)vs › | $900.50M | 6.16 |
| CeriBell, Inc. (CBLL)vs › | $928.50M | N/A |
| Bioventus Inc. (BVS)vs › | $892.39M | 16.91 |
| MoonLake Immunotherapeutics (MLTX)vs › | $941.25M | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $883.79M | N/A |
| Kura Oncology, Inc. (KURA)vs › | $947.22M | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $948.62M | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $863.38M | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $978.26M | N/A |
Trailing P/E
43.8
reported TTM EPS
Forward P/E
42.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.74 implies +2.8% EPS growth vs the reported trailing $0.72.
At the dated quote price of $31.30, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.74 | $0.73 – $0.75 | 2 | 42.4x |
| 2027-12-31 | $0.83 | $0.80 – $0.85 | 3 | 37.9x |
| 2028-12-31 | $0.00 | $0.00 – $0.00 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
